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Key Points
Question
Which processes of care are associated with reduced risk of mortality or recurrent stroke after transient
ischemic attack or nonsevere ischemic stroke?
Findings
In this cohort study of 8076 patients with transient ischemic attack or nonsevere ischemic stroke, only 1216
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(15.3%) received without-fail care, defined as receiving all guideline-concordant processes of care for
which they were eligible (ie, brain imaging, carotid artery imaging, antihypertensive intensification, high- or
moderate-potency statin therapy, antithrombotics, and anticoagulation for atrial fibrillation). Receiving all 6
processes was associated with lower risk of death (31.2% reduction at 1 year) but not lower risk of recurrent
stroke.
Meaning
Clinicians should ensure that patients with transient ischemic attack and nonsevere ischemic stroke receive
all guideline-concordant processes of care for which they are eligible.
Abstract
Importance
Early evaluation and management of patients with transient ischemic attack (TIA) and nonsevere ischemic
stroke improves outcomes.
Objective
To identify processes of care associated with reduced risk of death or recurrent stroke among patients with
TIA or nonsevere ischemic stroke.
Design, Setting, and Participants
This cohort study included all patients with TIA or nonsevere ischemic stroke at Department of Veterans
Affairs emergency department or inpatient settings from October 2010 to September 2011. Multivariable
logistic regression was used to model associations of processes of care and without-fail care, defined as
receiving all guideline-concordant processes of care for which patients are eligible, with risk of death and
recurrent stroke. Data were analyzed from March 2018 to April 2019.
Main Outcomes and Measures
Risk of all-cause mortality and recurrent ischemic stroke at 90 days and 1 year was calculated. Overall, 28
processes of care were examined. Without-fail care was assessed for 6 processes: brain imaging, carotid
artery imaging, hypertension medication intensification, high- or moderate-potency statin therapy,
antithrombotics, and anticoagulation for atrial fibrillation.
Results
Among 8076 patients, the mean (SD) age was 67.8 (11.6) years, 7752 patients (96.0%) were men, 5929
(73.4%) were white, 474 (6.1%) had a recurrent ischemic stroke within 90 days, 793 (10.7%) had a
recurrent ischemic stroke within 1 year, 320 (4.0%) died within 90 days, and 814 (10.1%) died within 1
year. Overall, 9 processes were independently associated with lower odds of both 90-day and 1-year
mortality after adjustment for multiple comparisons: carotid artery imaging (90-day adjusted odds ratio
[aOR], 0.49; 95% CI, 0.38-0.63; 1-year aOR, 0.61; 95% CI, 0.52-0.72), antihypertensive medication class
(90-day aOR, 0.58; 95% CI, 0.45-0.74; 1-year aOR, 0.70; 95% CI, 0.60-0.83), lipid measurement (90-day
aOR, 0.68; 95% CI, 0.51-0.90; 1-year aOR, 0.64; 95% CI, 0.53-0.78), lipid management (90-day aOR, 0.46;
95% CI, 0.33-0.65; 1-year aOR, 0.67; 95% CI, 0.53-0.85), discharged receiving statin medication (90-day
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aOR, 0.51; 95% CI, 0.36-0.73; 1-year aOR, 0.70; 95% CI, 0.55-0.88), cholesterol-lowering medication
intensification (90-day aOR, 0.47; 95% CI, 0.26-0.83; 1-year aOR, 0.56; 95% CI, 0.41-0.77),
antithrombotics by day 2 (90-day aOR, 0.56; 95% CI, 0.40-0.79; 1-year aOR, 0.69; 95% CI, 0.55-0.87) or at
discharge (90-day aOR, 0.59; 95% CI, 0.41-0.86; 1-year aOR, 0.69; 95% CI, 0.54-0.88), and neurology
consultation (90-day aOR, 0.67; 95% CI, 0.52-0.87; 1-year aOR, 0.74; 95% CI, 0.63-0.87). Anticoagulation
for atrial fibrillation was associated with lower odds of 1-year mortality only (aOR, 0.59; 95% CI, 0.40-
0.85). No processes were associated with reduced risk of recurrent stroke after adjustment for multiple
comparisons. The rate of without-fail care was 15.3%; 1216 patients received all guideline-concordant
processes of care for which they were eligible. Without-fail care was associated with a 31.2% lower odds of
1-year mortality (aOR, 0.69; 95% CI, 0.55-0.87) but was not independently associated with stroke risk.
Conclusions and Relevance
Patients who received 6 readily available processes of care had lower adjusted mortality 1 year after TIA or
nonsevere ischemic stroke. Clinicians caring for patients with TIA and nonsevere ischemic stroke should
seek to ensure that patients receive all guideline-concordant processes of care for which they are eligible.
Introduction
Patients with transient ischemic attack (TIA) and nonsevere ischemic stroke are at high risk of recurrent
vascular events.  However, studies have demonstrated that timely delivery of guideline-concordant care
can dramatically reduce this risk.  Studies reporting risk reductions of at least 70% for recurrent events
among patients with TIA or nonsevere ischemic stroke have emphasized early evaluation and management;
however, these studies differed in terms of the processes of care that were provided.  The American Heart
Association/American Stroke Association (AHA/ASA) stroke prevention guidelines recommend a broad
range of processes, including diagnostic processes (eg, brain imaging) and secondary prevention
interventions (eg, hypertension management).  Our objective was to identify the guideline-concordant
processes of care that were associated with a reduction in the risk of recurrent ischemic stroke or death
among patients with TIA or nonsevere stroke, adjusting for baseline patient characteristics.
Methods
This study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
reporting guideline. Human subjects approvals were obtained from the Indiana University School of
Medicine Institutional Review Board and the Richard L. Roudebush VA Medical Center Research and
Development Committee. Given that data were obtained from administrative sources, we obtained a waiver
of written informed consent.
Cohort Construction
We identified patients with TIA or ischemic stroke (minor or major) cared for in Department of Veterans
Affairs (VA) emergency departments or inpatient settings in fiscal year 2011 (October 2010 to September
2011) using primary discharge codes for TIA (International Classification of Diseases, Ninth Revision
[ICD-9] codes: 435.0, 435.1, 435.3, 435.8, and 435.9) or ischemic stroke (ICD-9 codes: 433.X1, 434.00,
434.X1, and 436).  Electronic health record data did not include a measure of stroke severity; therefore,
we used a validated approach to identify and exclude patients with major stroke (ie, length of stay >6 days,
ventilator use, feeding tube use, coma, intensive care unit stay, inpatient rehabilitation stay, or
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thrombolysis).  Patients transferred to non–Veterans Health Administration (VHA) facilities were
excluded because we could not assess quality of care.
Outcomes
The 4 primary outcomes were 90-day and 1-year risk of all-cause mortality and recurrent ischemic stroke.
We chose a 90-day end point because this timeframe has been used in TIA and nonsevere ischemic stroke
studies  and a 1 year end point because some processes (eg, hypertension control) are thought to improve
outcomes during longer time horizons. Ischemic stroke outcome events included emergency department or
inpatient visits with a diagnosis code used for cohort construction. Ischemic stroke events occurring the day
after discharge from the index event were not considered recurrent because medical record review indicated
that the second visit was nearly always a continuation of care for the index event. All patients were included
in the mortality outcomes. Patients transferred to non-VHA facilities or who died during the index event
were excluded from recurrent stroke outcomes.
Processes of Care
Overall, 28 processes of care were evaluated using electronic quality measures (eQMs) previously validated
against medical record review.  The processes were AHA/ASA recommended elements of care ; some
were similar to The Joint Commission stroke core measure set processes  and some were in the AHA/ASA
Performance Measures Set.  To our knowledge, neither organization has a TIA-specific measure set.
Numerator, denominator, and exclusion definitions are in eTable 1 in the Supplement. The processes
included diagnostic and therapeutic components of care: carotid artery imaging; carotid stenosis procedure
(ie, endarterectomy or stent); antihypertensive medication intensification (ie, new medication or increased
dosage of existing medication); hypertension control (ie, mean blood pressure <140/90 mm Hg in the 90
days after discharge); antihypertensive medication class  (ie, angiotensin-converting enzyme inhibitor or
angiotensin receptor blocker for patients with chronic kidney disease; thiazide for black patients; thiazide,
angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker for others); lipid measurement;
lipid management (ie, cholesterol-reducing medication if low-density lipoprotein cholesterol [LDL-C] levels
≥100 mg/dL [to convert millimoles per liter, multiply by 0.0259] or no measurement or if LDL-C <100
mg/dL or missing but patient is using existing lipid-lowering medication); discharged receiving statin
medication; cholesterol-lowering medication intensification (ie, if LDL-C ≥100 mg/dL or no measurement
among patients on submaximal lipid-lowering regimen); high- or moderate-potency statin prescription (ie,
high-potency statin if patient is aged <75 years; moderate- or high-potency statin if patient is aged ≥75
years); oral hypoglycemic medication intensification; hemoglobin A  measurement; electrocardiography;
telemetry; Holter monitor use; antithrombotics at day 2; antithrombotics at discharge; anticoagulation for
atrial fibrillation or flutter; international normalized ratio (INR) measurement; anticoagulation quality (ie,
INR 2-3 within 30 days of discharge); brain imaging; deep vein thrombosis prophylaxis; rehabilitation needs
assessment; speech-language pathology consultation; substance-use treatment referral for patients with
alcohol use disorder; nicotine replacement therapy for smokers; polysomnography; and neurology
consultation.
For each process, patients were classified as ineligible, eligible and passed, or eligible and failed. The
carotid stenosis measure was assessed in the 14 days after presentation; patients with an outcome event in
the 14 days after presentation were excluded. For measures assessed during 30 days after discharge, patients
with outcomes prior to the 30-day mark were excluded. For the 2 measures assessed during 90 days after
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discharge (ie, hypertension control and polysomnography), we reported outcomes at 1 year and excluded
patients with events prior to 90 days.
A variety of data sources were used to construct the eQMs.  Veterans Health Administration Central Data
Warehouse inpatient and outpatient data files in the 5 years before the event were used to identify medical
history, health care utilization, and procedures (using Current Procedural Terminology, Healthcare
Common Procedures Coding System, and ICD-9 procedure codes).  Pharmacy Benefits Management data
were used to identify medications. Data from the VHA Central Data Warehouse were also used for vital
signs, laboratory data, allergies, orders, and consultations. Linked VA/US Centers for Medicare & Medicaid
Services data were used to identify hospitalizations in non-VHA facilities. Veterans Affairs Fee Basis data
were used to identify inpatient and outpatient use and medical history. The date of death was obtained from
VA Vital Status files.
Without-Fail Care
Our goal was to identify the processes of care that were associated with improvements in vascular risk and
could be implemented across health care systems. It might not be possible to identify individual processes
that confer benefit because patients may receive several processes at the same time or through a shared
structure of care (eg, an admission order set). Although the VA system does not use a specific TIA or stroke
admission order set or care pathway, we hypothesized that a bundle of processes might be routinely ordered,
and therefore, we examined the 6 processes that were found to be effective in acute TIA management
studies (ie, brain imaging, carotid artery imaging, hypertension medication intensification, high- or
moderate-potency statin therapy, antithrombotics, and anticoagulation for atrial fibrillation).  The 6 without-
fail processes should be routinely available because they do not require advanced structures of care. A
without-fail care rate  was calculated for patients who were eligible for at least 1 of the 6 processes.
Patients who received all without-fail care processes for which they were eligible were classified as passing
the without-fail care rate.
Statistical Analysis
Patient characteristics, medical history, concomitant comorbidities, the final index event diagnosis (TIA or
nonsevere ischemic stroke), pre–index event inpatient and outpatient use, and index event symptoms were
compared among patients with outcomes and patients without outcomes. Continuous variables were
summarized using means and SDs or medians and ranges. The Wilcoxon rank sum test was used to test
differences in continuous variables, and Fisher exact or χ  tests were used to compare categorical variables
between groups.
Multivariable modeling was conducted in 2 phases for each of the 4 outcomes. First, we constructed risk-
adjustment models and then used the risk-adjustment models to assess associations of processes with
outcomes. First, 4 logistic regression models with random facility effects (to account for clustering of
patients within facilities) were used to model the outcomes. Independent variables based on patient and
facility factors (but not eQMs) were divided into 2 types: those which clinical judgment deemed a priori
confounders were forced into the model and those eligible for potential inclusion in the final model based on
backward variable selection (P < .25 to enter, P < .05 to stay). All tests were 2-tailed.
Second, using the models built in the first phase, the eQMs were included individually as covariates by
creating 2 indicator variables for each process: (1) passing among eligible patients and (2) not eligible. The
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reference category was being eligible and failing; therefore, the results can be interpreted as passing vs
failing. Including patients who were not eligible allowed all cohort members to be included in each model
and facilitated our identification of processes that were most closely associated with outcomes. Each eQM
was evaluated in a separate risk-adjusted model that did not include other eQMs. To enhance the clarity of
tables, we present odds ratios (ORs), 95% CIs, and P values for passing the process with failing as the
reference (data for ineligible patients are in eTables 2-5 in the Supplement). Statistical significance was set
at P < .05, and tests were 2-tailed. We adjusted for multiple comparisons using the false discovery rate
within each domain of interest (each process and the without-fail rate).
We conducted 3 sensitivity analyses. First, we repeated the modeling with patients 65 years or older because
Centers for Medicare & Medicaid Services data for this population augments outcome data available from
VA sources (ie, hospitalizations for ischemic stroke at non-VHA facilities that were not paid for by the VA).
Second, we examined the outcomes of quality of care for patients with TIA vs nonsevere ischemic stroke.
Third, we examined 3 medication measures to evaluate whether prior medication use (eg, being prescribed a
statin before the index TIA or nonsevere ischemic stroke event) accounted for the association of processes
with outcomes. Patients who passed each medication measure were classified into 2 groups: passed and
taking medication before the index event vs passed and taking new medication after the index event. These
2 variables were entered in the final logistic regression models (the reference group included patients who
failed the measure). Data analyses were performed using SAS software version 9.2 (SAS Institute).
Results
Among 8076 patients, 3863 (47.8%) had TIA and 4213 (52.2%) had nonsevere ischemic stroke. A total of
474 of 7802 at risk (6.1%) had a recurrent stroke within 90 days, and 793 of 7387 at risk (10.7%) had a
recurrent stroke within 1 year; 320 of 8076 (4.0%) died within 90 days, and 814 of 8076 (10.1%) died
within 1 year. The mean (SD) age was 67.8 (11.6) years, 7752 (96.0%) were men, and 5929 (73.4%) were
white (Table 1). The multivariable risk-adjustment models are provided in Table 2. The final risk-
adjustment model included 25 patient-level characteristics (included in Table 1) and no facility-level
characteristics. The C statistics for the risk-adjustment models were 0.815 for 90-day mortality, 0.789 for 1-
year mortality, 0.657 for 90-day recurrent stroke, and 0.659 for 1-year recurrent stroke.
The associations of individual processes with outcomes are shown in Table 3. Overall, 9 processes were
independently associated with lower odds of 90-day mortality after adjustment for multiple comparisons:
carotid artery imaging (adjusted OR [aOR], 0.49; 95% CI, 0.38-0.63), antihypertensive medication class
(aOR, 0.58; 95% CI, 0.45-0.74), lipid measurement (aOR, 0.68; 95% CI, 0.51-0.90), lipid management
(aOR, 0.46; 95% CI, 0.33-0.65), discharged receiving statin medication (aOR, 0.51; 95% CI, 0.36-0.73),
cholesterol-lowering medication intensification (aOR, 0.47; 95% CI, 0.26-0.83), antithrombotics by day 2
(aOR, 0.56; 95% CI, 0.40-0.79), antithrombotics at discharge (aOR, 0.59; 95% CI, 0.41-0.86), and
neurology consultation (aOR, 0.67; 95% CI, 0.52-0.87). For 1-year mortality, 10 processes were
independently associated with lower risk after adjustment for multiple comparisons: carotid artery imaging
(aOR, 0.61; 95% CI, 0.52-0.72), antihypertensive medication class (aOR, 0.70; 95% CI, 0.60-0.83), lipid
measurement (aOR, 0.64; 95% CI, 0.53-0.78), lipid management (aOR, 0.67; 95% CI, 0.53-0.85),
discharged receiving statin medication (aOR, 0.70; 95% CI, 0.55-0.88), cholesterol-lowering medication
intensification (aOR, 0.56; 95% CI, 0.41-0.77), antithrombotics by day 2 (aOR, 0.69; 95% CI, 0.55-0.87),
antithrombotics at discharge (aOR, 0.69; 95% CI, 0.54-0.88), anticoagulation for atrial fibrillation (aOR,
0.59; 95% CI, 0.40-0.85), and neurology consultation (aOR, 0.74; 95% CI, 0.63-0.87). No process was
20
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independently associated with recurrent stroke outcomes after adjustment for multiple comparisons. The
pass rates for the processes and complete model results are provided in eTables 2-5 in the Supplement; raw
P values and P values adjusted for multiple comparisons are provided in eTable 8 in the Supplement.
Without-Fail Care
Among 8076 patients, 143 were not eligible for at least 1 of the 6 without-fail processes, leaving 7933
eligible. The without-fail rate was 15.3%, meaning that only 1216 patients (15.3%) received all the
processes of care for which they were eligible among the 6 without-fail processes. Receiving without-fail
care was associated with a 31.2% reduction in the odds of 1-year mortality (aOR, 0.69; 95% CI, 0.55-0.87)
but was not independently associated with 90-day mortality or stroke outcomes after adjustment for multiple
comparisons (Table 3) (eTable 8 in the Supplement).
Sensitivity Analysis
In analyses restricted to patients 65 years and older, the results were similar to the main results (eTable 6 in
the Supplement). The magnitude of the association of the without-fail care rate with outcomes was similar
to the main analysis, but the aORs were modestly higher when restricted to the population 65 years and
older (eTable 6 in the Supplement). The magnitude of the association of the without-fail care rate with
mortality was nearly identical when comparing patients with TIA with patients with nonsevere ischemic
stroke; however, the aORs for the without-fail care rate and recurrent stroke risk were somewhat lower
among patients with nonsevere ischemic stroke compared with patients with TIA (eTable 6 in the
Supplement). For medication-based processes, the aORs were very similar for patients who were taking
medication before the index event and patients who were given a new prescription after the index event
(eTable 7 in the Supplement).
Discussion
These results support the association of guideline-concordant processes with improved outcomes for
patients with TIA and nonsevere ischemic stroke. The 6 without-fail care processes (ie, brain imaging,
carotid artery imaging, antihypertensive intensification, high- or moderate-potency statin therapy,
antithrombotics, and anticoagulation for atrial fibrillation) can be provided routinely at diverse medical
centers because they do not require specialized structures of care. Given the strength of the prospective trial
evidence as well as the current findings supporting the association of these processes with improved
outcomes, health care systems should prioritize providing patients with TIA or nonsevere ischemic stroke
with the guideline-concordant processes of care for which they are eligible.
The individual processes that were associated with improved outcomes included carotid stenosis
management, hyperlipidemia, anticoagulation for atrial fibrillation, antithrombotics, and neurology
consultation. These data support the AHA/ASA secondary prevention recommendations.  Although carotid
artery screening and intervention for symptomatic carotid stenosis are endorsed by guidelines, these
processes are not currently the focus of existing quality measurement programs.
The observed recurrent event rates are similar to those from other settings.  For example, 90-day
recurrent TIA and stroke rates have been reported in the 8.5%  to 9.9%  range. Johnston et al  reported a
90-day stroke rate of 10.5% for patients with TIA, but those data were from a cohort in 1997 to 1998.
However, data from Australia indicated that only 4.2% of patients with TIA or nonsevere ischemic stroke
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who were treated in stroke units had recurrent stroke in 90 days;  it may be that high-quality care provided
in specialized stroke units conferred a lower stroke recurrence rate.  The TIAregistry.org project (2009-
2011) reported a 90-day recurrent stroke rate of 3.7%, a 1-year recurrent stroke rate of 5.1%, and a 1-year
mortality rate of 1.8%; most patients (78%) received early stroke specialist care.  We similarly observed
that early neurology consultation was associated with a reduction in mortality.  Therefore, the difference in
risk of mortality between the TIAregistry.org project and the current cohort may be owing to differences in
neurology consultation rates. We relied on emergency department and inpatient use to identify recurrent
stroke events; therefore, the reported recurrent stroke rates underestimate actual rates for patients seeking
care at non-VHA facilities. It was for this reason that we conducted sensitivity analyses focused on patients
65 years and older for whom we had additional health care utilization data; the results of this analysis
supported the overall findings.
We were surprised that not more individual processes of care were independently associated with improved
outcomes. Our analyses may have been limited by relatively high pass rates on several processes. For
example, although antithrombotic medications were associated with lower odds of mortality, they were not
associated with recurrent stroke risk. A meta-regression of trials from the 1970s to 1990s  indicated that
approximately 14% of patients with stroke have a recurrent stroke during 32 months of follow-up, and the
recurrent stroke risk can be reduced by 15% (95% CI, 6%-23%) with aspirin. It may be that our cohort of
patients with TIA and nonsevere ischemic stroke, who had a 1-year recurrent stroke rate of 10.7% and a
pass rate of antithrombotics at discharge of 87%, may have included too few eligible patients who did not
receive antithrombotics to detect differences in recurrent stroke risk. However, among 67 892 patients in the
Get With the Guidelines–Stroke cohort, aspirin use was also not statistically associated with a reduction in
1-year recurrent stroke risk.  Therefore, it may be that the effect of antithrombotics on stroke risk is less
robust now than was observed in the clinical trials, many of which were conducted before the advent of
high-potency statins.
Although several risk prediction scores have been validated for patients with stroke and TIA, we did not rely
on any single risk adjustment score.  Because the clinical features of cerebrovascular events are
not routinely captured in electronic health record data, we could not use the age, blood pressure, clinical
features, duration of symptoms, and diabetes (ABCD ) score, but we did include 3 of its components (age,
blood pressure, diabetes). We evaluated a comprehensive set of risk-adjustment variables taken from the
literature about post-TIA risk prediction. The final model included variables with robust associations with
postevent outcomes (Table 2).
Given that these data were derived from an observational cohort, we cannot exclude the possibility of
confounding. We must consider that unmeasured confounders bias the assessment of the associations of
patient characteristics with outcomes as well as of processes with outcomes. The observation that some
clinical characteristics were associated with lower odds of death might be because of confounding. For
example, patients with prior carotid endarterectomy or carotid stent had lower odds of 90-day mortality than
patients without carotid interventions (Table 2). It may be that surgeons favor patients with strong
performance status, and thereby, the carotid intervention variable is a surrogate for good health. Although
we included a broad range of patient characteristics in the risk adjustment, we recognize that the risk of
confounding cannot be eliminated in observational cohort studies.
A related methodological issue is confounding by indication for the processes. We observed that patients
who were not eligible for a given process generally had higher odds of poor outcomes than patients who
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were eligible for that process. For example, patients who were eligible for carotid imaging and received the
process had lower odds of 90-day mortality compared with patients who were eligible but did not receive
carotid imaging (aOR, 0.49; 95% CI, 0.38-0.63). However, patients who were not eligible for carotid
imaging had higher odds of 90-day mortality compared with patients who were eligible but did not receive
the process (eTable 2 in the Supplement). This observation is clinically expected because patients with very
high disease severity (eg, hospice) were generally not eligible for processes (eTable 1 in the Supplement).
Similar to findings from other cohort studies, we also observed that some processes were associated with an
increased risk of adverse events.  For example, the observation that rehabilitation needs assessment was
associated with a higher odds of recurrent stroke (albeit not statistically significant) may be owing to
confounding by stroke severity (ie, patients with severe deficits were more likely to have rehabilitation
consultations); we did not have a measure of disease severity in the risk-adjustment model.
We could have used 2 alternative methodological strategies: (1) the cohort could have been restricted to
patients who were eligible for all processes of care, or (2) propensity analyses could have been conducted
for each process. We favored including all patients in the study because some key processes (eg,
anticoagulation for atrial fibrillation) are relevant to small subpopulations (ie, patients with atrial
fibrillation), limiting the sample size and the generalizability. Propensity score adjustment is used to reduce
bias when estimating the effect of an intervention on an outcome and is generally applied when
investigating associations of single interventions with outcomes, especially when the characteristics of
patients who receive an intervention differ from patients who do not receive an intervention.  Given that
we were interested in evaluating a broad range of processes, propensity score adjustment would have
necessitated the development and presentation of more than 2 dozen models. Our approach involved
defining eligibility for processes based on clinical guidelines. The risk-adjusted results (Table 3) describe
the association of processes of care with outcomes among patients who were eligible for those processes.
Strengths and Limitations
The strengths of this study were its national scope, relatively large sample size, and inclusion of a
comprehensive set of processes as well as a bundle of care. This study had limitations. First, as described
earlier, although the modeling included a broad range of potential confounders,  the possibility for residual
confounding exists, especially because we did not have brain imaging results  or data on stroke severity,
stroke type, or stroke location. Second, without-fail processes were identified a priori; therefore, it is
possible that the without-fail measure did not include processes with the strongest associations with
outcomes. Future studies might consider identifying all-or-none quality measures empirically. Third, this
study focused on veterans seeking care within VHA facilities, so the results may not generalize to other
populations or health care settings.
Conclusions
In this study, individual processes of care and a 6-item without-fail care measure were associated with
clinically meaningful reductions in risk of stroke and death. Widespread implementation of these processes
should be strongly considered for patients with TIA and nonsevere ischemic stroke. In addition, health care
systems should consider routinely measuring key processes of care for patients with TIA in addition to the
quality measurement that exists for patients with stroke.
Notes
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Figures and Tables
Table 1.
Baseline Characteristics for 8076 Patients with TIA or Nonsevere Stroke
Characteristic No. (%)
Age, y  
Mean (SD) 67.8 (11.6)
Median (IQR) [range] 65 (60-77) [20-101]
Men 7752 (96.0)
Race  
White 5929 (73.4)
Processes of Care Associated With Risk of Mortality and Recurrent Stroke Among Patients With Transient Ischemic Attack and Nonsevere Ischemic Stroke
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613337/?report=printable[9/3/2019 11:38:32 AM]
Black 1726 (21.4)
Other 421 (5.2)
Stroke in prior 30 d 764 (9.5)
TIA in prior 30 d 312 (3.9)
Carotid artery stenosis 1294 (16.0)
Carotid endarterectomy or stent 544 (6.7)
Diabetes 3320 (41.1)
Hypertension 6549 (81.1)
Hyperlipidemia 5824 (72.1)
Congestive heart failure 1859 (23.0)
Myocardial infarction, CABG, or PCI/stent 2819 (34.9)
Atrial fibrillation 1077 (13.3)
Other cardiac arrhythmia 2150 (26.6)
Peripheral arterial disease 2244 (27.8)
Chronic kidney disease 1549 (19.2)
Charlson Comorbidity Index score, median (IQR) [range] 1 (0-3) [0-18]
Concomitant medical conditions
Congestive heart failure, ie, BNP >200 pg/mL 84 (1.0)
Myocardial infarction, ie, troponin >0.1 ng/mL 22 (0.3)
Current tobacco smoker 2748 (34.0)
Index event diagnosis
TIA 3863 (47.8)
Minor ischemic stoke 4213 (52.2)
Open in a separate window
Abbreviations: BNP, B-type natriuretic peptide; CABG, coronary artery bypass grafting; IQR, interquartile range;
PCI, percutaneous coronary intervention; TIA, transient ischemic attack.
SI conversion factors: To convert BNP to nanograms per liter, multiply by 1.0; troponin to micrograms per liter,
multiply by 1.0.
Table 2.
Final Risk-Adjustment Model for 90-Day and 1-Year Mortality and Recurrent Ischemic
Stroke Events
90-d Outcomes 1-y Outcomes
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Patient Characteristic
Mortality
Recurrent
Ischemic Stroke
Mortality
Recurrent
Ischemic Stroke
OR (95%
CI)
P
Value
OR (95%
CI)
P
Value
OR (95%
CI)
P
Value
OR (95%
CI)
P
Value
No./total No. (%) 320/8076
(4.0)
474/7802
(6.1)
814/8076
(10.1)
793/7387
(10.7)
Age 1.06 (1.05-
1.07)
<.001 1.00 (0.99-
1.01)
.31 1.06
(1.05-
1.07)
<.001 1.00
(0.99-
1.01)
.42
Female sex 0.93 (0.42-
2.05)
.86 0.43 (0.21-
0.87)
.02 0.71
(0.41-
1.23)
.22 0.77
(0.50-
1.20)
.26
Race         
Black 0.92 (0.66-
1.26)
.59 0.99 (0.78-
1.26)
.96 0.87
(0.71-
1.08)
.22 1.08
(0.90-
1.30)
.42
Other 0.62 (0.31-
1.25)
.18 0.86 (0.54-
1.35)
.50 1.00
(0.69-
1.46)
>.99 1.00
(0.70-
1.42)
>.99
Stroke in prior 30 d 1.26 (0.89-
1.77)
.19 1.56 (1.18-
2.07)
.002 1.06
(0.83-
1.36)
.64 1.58
(1.26-
1.98)
<.001
TIA in prior 30 d prior to
index event
1.02 (0.56-
1.86)
.95 0.87 (0.52-
1.45)
.60 0.96
(0.65-
1.43)
.86 0.92
(0.62-
1.37)
.69
Carotid artery stenosis 0.80 (0.59-
1.10)
.17 1.31 (1.01-
1.70)
.04 0.90
(0.73-
1.11)
.32 1.30
(1.06-
1.60)
.01
Carotid endarterectomy or
stent
0.55 (0.31-
0.97)
.04 0.92 (0.63-
1.34)
.66 0.83
(0.60-
1.14)
.24 0.91
(0.67-
1.23)
.53
Diabetes 0.78 (0.60-
1.02)
.07 1.19 (0.96-
1.49)
.12 0.83
(0.70-
1.00)
.05 1.11
(0.94-
1.33)
.23
Hypertension 1.07 (0.70-
1.62)
.76 0.92 (0.70-
1.22)
.56 0.87
(0.67-
1.13)
.30 1.02
(0.81-
1.28)
.90
Hyperlipidemia 0.70 (0.52-
0.95)
.02 0.97 (0.76-
1.23)
.80 0.75
(0.61-
0.92)
.006 0.89
(0.73-
1.08)
.23
Congestive heart failure 1.17 (0.88-
1.56)
.29 0.93 (0.72-
1.21)
.60 1.10
(0.91-
.32 1.00
(0.81-
>.99
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1.34) 1.23)
Myocardial infarction,
CABG, or PCI/stent
1.06 (0.80-
1.39)
.70 1.15 (0.92-
1.45)
.22 1.08
(0.90-
1.30)
.43 1.15
(0.95-
1.38)
.15
Atrial fibrillation 1.66 (1.24-
2.21)
.001 1.23 (0.91-
1.66)
.17 1.55
(1.27-
1.90)
<.001 1.18
(0.93-
1.50)
.18
Other cardiac arrhythmia 1.02 (0.78-
1.35)
.87 0.86 (0.67-
1.09)
.21 0.85
(0.71-
1.03)
.09 0.86
(0.71-
1.04)
.12
Peripheral arterial disease 1.47 (1.13-
1.91)
.004 1.07 (0.85-
1.35)
.56 1.28
(1.07-
1.52)
.007 1.15
(0.96-
1.38)
.13
Chronic kidney disease 0.62 (0.46-
0.85)
.003 0.97 (0.73-
1.28)
.82 0.82
(0.67-
1.01)
.06 0.96
(0.77-
1.19)
.72
Charlson Comorbidity Index
score
1.22 (1.16-
1.29)
<.001 1.01 (0.95-
1.07)
.82 1.23
(1.18-
1.28)
<.001 1.08
(1.03-
1.13)
.001
Congestive heart failure, ie,
BNP >200 pg/mL
2.12 (1.08-
4.15)
.03 0.19 (0.03-
1.40)
.10 2.14
(1.28-
3.57)
.004 0.11
(0.02-
0.77)
.03
Myocardial infarction, ie,
troponin >0.1 ng/mL
5.36 (1.73-
16.65)
.004 7.26 (2.65-
19.89)
<.001 4.00
(1.51-
10.60)
.005 3.98
(1.43-
11.05)
.008
Current tobacco smoker 1.19 (0.89-
1.58)
.24 1.03 (0.84-
1.27)
.78 1.14
(0.95-
1.38)
.16 1.00
(0.84-
1.18)
.96
Index event diagnosis of
stroke
2.09 (1.62-
2.69)
<.001 2.00 (1.63-
2.45)
<.001 1.55
(1.32-
1.82)
<.001 1.77
(1.51-
2.08)
<.001
No. of hospitalizations pre–
index event
1.06 (0.99-
1.13)
.07 1.08 (1.02-
1.15)
.008 1.11
(1.06-
1.17)
<.001 1.07
(1.02-
1.13)
.01
Speech deficit 1.32 (0.99-
1.76)
.06 1.31 (1.03-
1.66)
.03 1.26
(1.03-
1.53)
.02 1.21
(1.00-
1.47)
.06
APACHE score 1.05 (1.03-
1.06)
<.001 1.00 (0.98-
1.01)
.75 1.04
(1.02-
1.05)
<.001 1.02
(1.00-
1.03)
.01
Open in a separate window
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Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; BNP, B-type natriuretic peptide;
CABG, coronary artery bypass grafting; OR, odds ratio; PCI, percutaneous coronary intervention; TIA, transient
ischemic attack.
SI conversion factors: To convert BNP to nanograms per liter, multiply by 1.0; troponin to micrograms per liter,
multiply by 1.0.
Table 3.
Risk-Adjusted Association of Passing an Individual Process of Care Measure With Recurrent
Vascular Events
Process Measures Risk-Adjusted OR (95% CI)
90-d Outcomes 1-y Outcomes
Mortality
Risk
Recurrent
Stroke Risk
Mortality
Risk
Recurrent
Stroke Risk
No./total No. (%) 320/8076
(4.0)
474/7802
(6.1)
814/8076
(10.1)
793/7387
(10.7)
Carotid
Carotid artery imaging ≤2 d after presentation or in
last 6 mo
0.49
(0.38-
0.63)
0.89 (0.73-
1.09)
0.61
(0.52-
0.72)
0.94 (0.80-
1.10)
Carotid stenosis procedure ≤14 d among patients
with procedure within 1 y
… 0.18 (0.04-
0.80)
0.82
(0.16-
4.15)
0.12 (0.03-
0.49)
Blood pressure
Hypertension medication intensification ≤2 d after
discharge
0.55
(0.28-
1.07)
0.97 (0.69-
1.38)
0.82
(0.58-
1.17)
1.04 (0.78-
1.37)
Mean blood pressure of <140/90 mm Hg during 90 d
postdischarge
NA NA 1.04
(0.79-
1.37)
0.69 (0.53-
0.90)
Guideline-concordant antihypertensive medication
class ≤2 d after discharge
0.58
(0.45-
0.74)
0.74 (0.60-
0.91)
0.70
(0.60-
0.83)
0.85 (0.72-
0.99)
Lipid management
Lipid measurement ≤2 d after presentation or in prior
180 d
0.68
(0.51-
0.90)
0.78 (0.62-
0.99)
0.64
(0.53-
0.78)
0.84 (0.70-
1.02)
Lipid management ≤2 d after discharge 0.46 0.73 (0.56- 0.67 0.86 (0.68-
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(0.33-
0.65)
0.96) (0.53-
0.85)
1.07)
Discharged receiving statin ≤2 d after discharge 0.51
(0.36-
0.93 (0.70-
1.23)
0.70
(0.55-
1.03 (0.81-
1.30)
    
 
  
        
       
      
     
  
 
Open in a separate window
Abbreviations: HbA , hemoglobin A ; INR, international normalized ratio; NA, not applicable; OR, odds ratio;
ellipsis, not calculated.
Each risk-adjusted OR was generated from a single multivariable model that included all of the covariates listed in
Table 2.
Overall, 6 processes of care were included in the without-fail measure: carotid artery imaging, hypertension
medication intensification, high- or moderate-potency statin therapy, brain imaging, antithrombotics at discharge,
and anticoagulation for atrial fibrillation. A patient passed the without-fail rate if they received all of the processes
for which they were eligible.
Too few patients were included to calculate 90-day mortality.
P value for this process of care and outcome was not statistically significant following false discovery rate
adjustment for multiple comparisons. All raw and adjusted P values for each comparison are provided in eTable 8
in the Supplement.
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